-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time -- SAN CARLOS, Calif. , Oct. 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the U.S.

Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitis SAN CARLOS, Calif. , Sept. 27, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry

SAN CARLOS, Calif. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: 2021 Virtual Wells Fargo Healthcare Conference Fireside Chat

-- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021 -- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis also under review by the European Medicines Agency and the Japan

SAN CARLOS, Calif. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at

MOUNTAIN VIEW, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market close on Monday, August 9, 2021 . ChemoCentryx executive management will host a conference call and

SAN CARLOS, Calif. , July 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of Anti-neutrophil

SAN CARLOS, Calif. , June 16, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Raymond James 2021 Human Health Innovations Conference on Wednesday, June 23

-- Abstract on ‘The Effect of Avacopan, a Complement C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis with Renal Disease’ honored on “Ten Best” list by the Paper Selection Committee of ERA-EDTA -- -- Abstract on the Phase II ACCOLADE Study of Avacopan for the

SAN CARLOS, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee (“Committee”) on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody